117 related articles for article (PubMed ID: 31976485)
1. JAK/STAT Pathway Mutations in T-ALL, Including the STAT5B N642H Mutation, are Sensitive to JAK1/JAK3 Inhibitors.
Govaerts I; Jacobs K; Vandepoel R; Cools J
Hemasphere; 2019 Dec; 3(6):e313. PubMed ID: 31976485
[No Abstract] [Full Text] [Related]
2. JAK/STAT-Activating Genomic Alterations Are a Hallmark of T-PLL.
Wahnschaffe L; Braun T; Timonen S; Giri AK; Schrader A; Wagle P; Almusa H; Johansson P; Bellanger D; López C; Haferlach C; Stern MH; Dürig J; Siebert R; Mustjoki S; Aittokallio T; Herling M
Cancers (Basel); 2019 Nov; 11(12):. PubMed ID: 31766351
[TBL] [Abstract][Full Text] [Related]
3.
Andersson EI; Brück O; Braun T; Mannisto S; Saikko L; Lagström S; Ellonen P; Leppä S; Herling M; Kovanen PE; Mustjoki S
Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32188095
[TBL] [Abstract][Full Text] [Related]
4. A Recurrent
Kieslinger M; Swoboda A; Kramer N; Freund P; Pratscher B; Neubauer HA; Steinborn R; Wolfesberger B; Fuchs-Baumgartinger A; Moriggl R; Burgener IA
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680385
[TBL] [Abstract][Full Text] [Related]
5. JAK3 as an Emerging Target for Topical Treatment of Inflammatory Skin Diseases.
Alves de Medeiros AK; Speeckaert R; Desmet E; Van Gele M; De Schepper S; Lambert J
PLoS One; 2016; 11(10):e0164080. PubMed ID: 27711196
[TBL] [Abstract][Full Text] [Related]
6. Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells.
Küçük C; Jiang B; Hu X; Zhang W; Chan JK; Xiao W; Lack N; Alkan C; Williams JC; Avery KN; Kavak P; Scuto A; Sen E; Gaulard P; Staudt L; Iqbal J; Zhang W; Cornish A; Gong Q; Yang Q; Sun H; d'Amore F; Leppä S; Liu W; Fu K; de Leval L; McKeithan T; Chan WC
Nat Commun; 2015 Jan; 6():6025. PubMed ID: 25586472
[TBL] [Abstract][Full Text] [Related]
7. Activation of JAK3, but not JAK1, is critical for IL-2-induced proliferation and STAT5 recruitment by a COOH-terminal region of the IL-2 receptor beta-chain.
Kirken RA; Rui H; Malabarba MG; Howard OM; Kawamura M; O'Shea JJ; Farrar WL
Cytokine; 1995 Oct; 7(7):689-700. PubMed ID: 8580378
[TBL] [Abstract][Full Text] [Related]
8. Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.
Losdyck E; Hornakova T; Springuel L; Degryse S; Gielen O; Cools J; Constantinescu SN; Flex E; Tartaglia M; Renauld JC; Knoops L
J Biol Chem; 2015 Nov; 290(48):29022-34. PubMed ID: 26446793
[TBL] [Abstract][Full Text] [Related]
9. JAK/STAT pathway directed therapy of T-cell leukemia/lymphoma: Inspired by functional and structural genomics.
Waldmann TA
Mol Cell Endocrinol; 2017 Aug; 451():66-70. PubMed ID: 28214593
[TBL] [Abstract][Full Text] [Related]
10. STAT5b gain-of-function disease in a child with mycobacterial osteomyelitis of the skull: rare presentation of an emerging disease entity.
Kobets AJ; Ahmad S; Boyke A; Oriko D; Holland R; Eisenberg R; Alavi SAN; Abbott R
Childs Nerv Syst; 2023 Aug; 39(8):2071-2077. PubMed ID: 37243811
[TBL] [Abstract][Full Text] [Related]
11. Delineation of the regions of interleukin-2 (IL-2) receptor beta chain important for association of Jak1 and Jak3. Jak1-independent functional recruitment of Jak3 to Il-2Rbeta.
Zhu MH; Berry JA; Russell SM; Leonard WJ
J Biol Chem; 1998 Apr; 273(17):10719-25. PubMed ID: 9553136
[TBL] [Abstract][Full Text] [Related]
12. Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers.
Jeong EG; Kim MS; Nam HK; Min CK; Lee S; Chung YJ; Yoo NJ; Lee SH
Clin Cancer Res; 2008 Jun; 14(12):3716-21. PubMed ID: 18559588
[TBL] [Abstract][Full Text] [Related]
13. Novel JAK3-Activating Mutations in Extranodal NK/T-Cell Lymphoma, Nasal Type.
Sim SH; Kim S; Kim TM; Jeon YK; Nam SJ; Ahn YO; Keam B; Park HH; Kim DW; Kim CW; Heo DS
Am J Pathol; 2017 May; 187(5):980-986. PubMed ID: 28284718
[TBL] [Abstract][Full Text] [Related]
14. Pathogenic and Therapeutic Relevance of JAK/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent.
Alunno A; Padjen I; Fanouriakis A; Boumpas DT
Cells; 2019 Aug; 8(8):. PubMed ID: 31443172
[TBL] [Abstract][Full Text] [Related]
15. Janus kinases in interleukin-2-mediated signaling: JAK1 and JAK3 are differentially regulated by tyrosine phosphorylation.
Liu KD; Gaffen SL; Goldsmith MA; Greene WC
Curr Biol; 1997 Nov; 7(11):817-26. PubMed ID: 9382798
[TBL] [Abstract][Full Text] [Related]
16. Differential substrate recognition capabilities of Janus family protein tyrosine kinases within the interleukin 2 receptor (IL2R) system: Jak3 as a potential molecular target for treatment of leukemias with a hyperactive Jak-Stat signaling machinery.
Witthuhn BA; Williams MD; Kerawalla H; Uckun FM
Leuk Lymphoma; 1999 Jan; 32(3-4):289-97. PubMed ID: 10037026
[TBL] [Abstract][Full Text] [Related]
17. Characterization of JAK1 Pseudokinase Domain in Cytokine Signaling.
Raivola J; Haikarainen T; Silvennoinen O
Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31892268
[TBL] [Abstract][Full Text] [Related]
18. Genomic Profiling of T-Cell Neoplasms Reveals Frequent
Greenplate A; Wang K; Tripathi RM; Palma N; Ali SM; Stephens PJ; Miller VA; Shyr Y; Guo Y; Reddy NM; Kozhaya L; Unutmaz D; Chen X; Irish JM; Davé UP
JCO Precis Oncol; 2018; 2018():. PubMed ID: 30079384
[TBL] [Abstract][Full Text] [Related]
19. EGF-induced MMP-9 expression is mediated by the JAK3/ERK pathway, but not by the JAK3/STAT-3 pathway in a SKBR3 breast cancer cell line.
Kim S; Choi JH; Lim HI; Lee SK; Kim WW; Cho S; Kim JS; Kim JH; Choe JH; Nam SJ; Lee JE; Yang JH
Cell Signal; 2009 Jun; 21(6):892-8. PubMed ID: 19385051
[TBL] [Abstract][Full Text] [Related]
20. Jak1 has a dominant role over Jak3 in signal transduction through γc-containing cytokine receptors.
Haan C; Rolvering C; Raulf F; Kapp M; Drückes P; Thoma G; Behrmann I; Zerwes HG
Chem Biol; 2011 Mar; 18(3):314-23. PubMed ID: 21439476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
